| [November 25, 2015] |
 |
Newron Pharmaceuticals to Present at the 27th Annual Piper Jaffray Healthcare Conference
Newron
Pharmaceuticals S.p.A. ("Newron") [Ticker: SIX: NWRN], a research
and development company focused on novel central nervous system (CNS)
and pain therapies, today announced that Stefan Weber, CEO, will present
at the 27th Annual Piper Jaffray Healthcare Conference in New
York, NY on Dec. 1, 2015, at 11:50 a.m. ET at the New York Palace Hotel.
About
Newron Pharmaceuticals
Newron (SIX: NWRN) is a
biopharmaceutical company focused on the development of novel therapies
for patients with diseases of the central nervous system (CNS) and pain.
The Company is headquartered in Bresso near Milan, Italy. Marketing
authorization in the EU for Xadago® (safinamide) for the
treatment of Parkinson's disease was granted by the EU Commission in
February 2015, followed by the launch by Zambon in the first key EU
country - Germany - in May 2015. The New Drug Application (NDA) has been
accepted for review by the FDA, as reported in March 2015. In November
2015, Swissmedic has granted marketing authorization to Zambon, Newron's
partner. Zambon has the rights to develop and commercialize safinamide
globally, excluding Japan and other key Asian territories, where Meiji
Seika has the rights to develop and commercialize the compound. Newron's
additional projects are based on highly promising treatments for rare
disease patients and are at various stages of clinical development. They
include sarizotan for patients with Rett syndrome, for which Newron
received Orphan Drug Designation in both the US and the EU, ralfinamide
for patients with specific rare pain indications, and NW-3509 as
potentially the first add-on therapy for the treatment of patients with
positive symptoms of schizophrenia. For additional information, please
visit http://www.newron.com.
Important Notices
This document contains forward-looking
statements, including (without limitation) about (1) Newron's ability to
develop and expand its business, successfully complete development of
its current product candidates and current and future collaborations for
the development and commercialisation of its product candidates and
reduce costs (including staff costs), (2) the market for drugs to treat
CNS diseases and pain conditions, (3) Newron's anticipated future
revenues, capital expenditures and financial resources, and (4)
assumptions underlying any such statements. In some cases these
statements and assumptions can be identified by the fact that they use
words such as "will", "anticipate", "estimate", "expect", "project",
"intend", "plan", "believe", "target", and other words and terms of
similar meaning. All statements, other than historical facts, contained
herein regarding Newron's strategy, goals, plans, future financial
position, projected revenues and costs and prospects are forward-looking
statements.
By their very nature, such statements and assumptions
involve inherent risks and uncertainties, both general and specific, and
risks exist that predictions, forecasts, projections and other outcomes
described, assumed or implied therein will not be achieved. Future
events and actual results could differ materially from those set out in,
contemplated by or underlying the forward-looking statements due to a
number of important factors. These factors include (without limitation)
(1) uncertainties in the discovery, development or marketing of
products, including without limitation negative results of clinical
trials or research projects or unexpected side effects, (2) delay or
inability in obtaining regulatory approvals or bringing products to
market, (3) future market acceptance of products, (4) loss of or
inability to obtain adequate protection for intellectual property
rights, (5) inability to raise additional funds, (6) success of existing
and entry into future collaborations and licensing agreements, (7)
litigation, (8) loss of key executive or other employees, (9) adverse
publicity and news coverage, and (10) competition, regulatory,
legislative and judicial developments or changes in market and/or
overall economic conditions.
Newron may not actually achieve the
plans, intentions or expectations disclosed in forward-looking
statements and assumptions underlying any such statements may prove
wrong. Investors should therefore not place undue reliance on them.
There can be no assurance that actual results of Newron's research
programmes, development activities, commercialisation plans,
collaborations and operations will not differ materially from the
expectations set out in such forward-looking statements or underlying
assumptions.
Newron does not undertake any obligation to publicly
up-date or revise forward looking statements except as may be required
by applicable regulations of the SIX Swiss Exchange where the shares of
Newron are listed.
This document does not contain or constitute an
offer or invitation to purchase or subscribe for any securities of
Newron and no part of it shall form the basis of or be relied upon in
connection with any contract or commitment whatsoever.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151125005707/en/
[ Back To TMCnet.com's Homepage ]
|
